Revance Therapeutics (STU:RTI) YoY EBITDA Growth : 1.63% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Revance Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 1.63%.

Revance Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.42.

Revance Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Revance Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics YoY EBITDA Growth Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

3.22

-13.36

8.95

-16.47

19.15

Revance Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															43.27	4.80	-51.41	64.58	1.63

Revance Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Revance Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-3.15	-	-3.896)	/	\| -3.896 \|
=	19.15 %

Revance Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.423	-	-0.43)	/	\| -0.43 \|
=	1.63 %

Revance Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (STU:RTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RVNC:USA

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics (STU:RTI) Headlines

No Headlines